In this blogpost, we discuss the significance of OHDSI, OMOP, and EHDEN in improving healthcare through data standardization and efficient analysis. We detail the advantages of OMOP CDM data warehouses for hospitals and showcase how LynxCare contributes to implementing these data warehouses.
LynxCare's comprehensive data assets* offer fresh insights into Immuno-Oncology, Breast Cancer, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Multiple Myeloma (MM), including comorbidity factors, treatment patterns, and staging.
In May 2022, the European Commission announced the launch of the European Health Data Space (EHDS), one of the central building blocks of a strong European Health Union. The EHDS will help the EU to achieve a quantum leap forward in the way healthcare is provided to people across Europe.
With over 2000 estimated patients and 579 endpoints measured, our granular and quality-controlled real-world dataset can unlock invaluable insights into the treatment and prognosis of immuno-oncology (IO), empowering clinicians to make informed decisions.
We discuss the potential of the abundant RWD for lung cancer presenting an invaluable resource when translated into RWE. While clinical trials are essential, they may not fully represent the real-world patient population. RWE complements clinical trial evidence by providing insights on treatment outcomes in broader, unselected patient groups, helping inform reimbursement decisions and ensuring access to innovative therapies.
In its latest report released in June 2023, the EMA highlights key opportunities and challenges to move towards an optimized usage of RWE across the spectrum of regulatory use cases. To push this transformative vision forward, the report presents a list of lessons learned and recommendations. Continue reading below.
A study published in Clinical Pharmacology &Therapeutics  looking at positive marketing authorization applications of new medicines by the European Medicines Agency (EMA) in 2018-2019, found that almost all evaluated medicines included RWE signatures in the discovery (98.2%) and lifecycle management (100%) phases. About half of the medicines had RWE signatures for the full development phase (48.6%) and for supporting regulatory decisions at the registration phase (46.8%), while over a third included RWE signatures for the early development (35.1%). Therapeutic areas such as oncology, hematology, and anti-infectives showed the highest use of RWE signatures in their full development phase.
Selecting patients for clinical studies can be a slow and tedious process. But it does not have to be. Emerging technologies are paving the way for faster and more efficient patient selection, and our Clinical REsearch Patient Selection (CREPS) project in collaboration with a renowned Belgian hospital is leading the change. In this blog post, we will dive into the world of real-world evidence (RWE) and explore how the use of big data and Natural Language Processing (NLP) can revolutionize the way we screen and select patients for clinical studies while always remaining 100% GDPR compliant. Let us explore how LynxCare’s technology can speed up and simplify your trials’ patient selection process.
A metanalysis published in the Heart journal identified 37 studies developing and applying NLP in various areas of cardiology. This systematic review found that the majority of NLP work in cardiology has been concentrated in a small number of clinical domains and NLP methods, with the most common applications being used for disease identification and classification purposes. Patient sample sizes ranged from 60 to 621,000. Data sources ranged from single centers to national healthcare system databases and registries, most of them taking place in the US.
ESMO Immuno-Oncology 2023 will take place from 6-8 December in Geneva. Don't miss out on the poster presentation of Dr. Verbiest (UZA): "Real-World Insights on Pan-Cancer Immune Checkpoint Inhibitor Treatment: Initial Findings of a Belgian Multicenter Study"
We are happy to announce the 5th edition of Big Data 4 Health! Join us for an engaging and dynamic evening that will serve as a platform to share know-how and experiences in the realm of big data for research and patient care.
The Molecular Analysis for Precision Oncology Congress (MAP) 2023 will take place on 4 and 5 October 2023 in Paris, France. Watch our for our joint poster presentation with UMCG: "Identifying EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC) Patients from the Netherlands through Automatic Data Processing".
Learn how you can gain access to deep insights from highly detailed RWD. Representative datasets of diverse European patient populations, to push your research studies forward faster and with the level of quality necessary to help improve the patient journey.
Come find our exhibit at the European OHDSI symposium on July 3rd in Rotterdam! We look forward to sharing how we help hospitals unlock their structured and unstructured data, harmonize them to the OMOP CDM, and set up clinical grade data warehouses to facilitate research and collaboration.
Meet us there together with our partner PSIH Group from May 23 to 25! Ready to innovate? Prepare your hospital for the France 2030 plan and the European Health Data Space. Find us at Stand L60 and discover how we can help address your hospital's challenges of today and tomorrow! On 23 May, at 12h15, we will be presenting our solution dedicated to healthcare data warehouses on the "command center" stage.
The ESC Heart Failure congress, world's leading event on heart failure, will cover the entire spectrum of heart failure, from prevention to diagnosis and treatment. On 21 May, Dr. Vanderheyden (OLV Hospital) will be presenting our joint study on the use of a systematic framework to diagnose aTTR-CM in a real-world heart failure population.
EACR: Defence is the Best Attack - Immuno-Oncology Breakthroughs
May 9, 2023 11:30 AM
At this conference, organized by the European Association for Cancer Research (EACR), the latest advances in the field of immuno-oncology, from the basic science to clinical studies, will be covered. Meet us at stand 3, and attend our spotlight session on Wednesday, 10 May, from 2.45 - 3.05pm!
On 25 April, we will be presenting at the DMEA, one of Europe's most important events for Digital Health. Clara L. Oeste, Senior Medical Writer, will discuss automated data extraction from electronic health records using NLP and federated OMOP databases: lessons learned in heart failure.
Meet us at the HIMMS conference in Chicago, there where the global healthcare and technology spaces unite. Contact us to schedule a meeting onsite or to have a quick chat over coffee/tea on the banks of Lake Michigan.
On 24 November 2022, pharma.be organizes a networking event for all its members. During this event in the shape of a trade fair, all partners and SMEs have the possibility to set up a company booth and participate to speed dating with pharma.be members on specific topics (real-world data & digital health and market access). Meet LynxCare there!
”We're an active contributor to establishing the pan-European Health Data Evidence Network (EHDEN) and are eager to contribute to building the European Health Data Space to make a more inclusive European healthcare system for all patients.”